Medidata Selected for Inaugural Fortune Future 50 List
October 19 2017 - 8:09AM
Business Wire
Named by Fortune as a top forward-looking,
innovative global company
Medidata (NASDAQ: MDSO), the leading global provider of
cloud-based technology and data analytics for clinical research,
today announced that it has been selected for the Fortune Future 50
list; a ranking celebrating the world’s most forward-looking,
innovative companies that are best set up for the future.
Fortune magazine, in partnership with The Boston Consulting
Group, ranked Medidata 11th in the Challengers category for the
inaugural 2017 Fortune Future 50 list, as a company that is
positioned for future growth.
"Every step we’ve taken since our doors opened in 1999 has been
about guaranteeing that we don't just facilitate efficient clinical
trials today, but solve the problems of the future,” said Mike
Capone, chief operating officer at Medidata. “We’ve made our mark
by redefining industry standards with data and analytics and more
to solve the most challenging problems for life sciences companies.
We believe in our employees and technology, together they are
creating new possibilities and hope for patients around the
world.”
The Fortune Future 50 was featured in a special edition of the
publication dedicated to the connective tissue of the modern
corporate enterprise – its technology. The list was compiled based
on a combination of external market potential and internal
capability-based lens. Rankings included five core beliefs;
Market: Valuable long-term growth opportunities; Strategy
Vitality: patterns of exploratory thinking, strong long-term
orientation; Technology & Investments: innovates in
emergent tech areas (AI, digital, etc.), makes appropriate
investments into organic growth; People: open to diverse
sources of management talent, provides leadership opportunities at
young age; Structure: tends to be more agile/youthful, track
record of sustained growth.
About Medidata
Medidata is reinventing global drug and medical device
development by creating the industry's leading cloud-based
solutions for clinical research. Through our advanced applications
and intelligent data analytics, Medidata helps advance the
scientific goals of life sciences customers worldwide, including
more than 850 global pharmaceutical companies, innovative biotech,
diagnostic and device firms, leading academic medical centers, and
contract research organizations.
The Medidata Clinical Cloud® brings a new level of quality and
efficiency to clinical trials that empower our customers to make
more informed decisions earlier and faster. Our unparalleled
clinical trial data assets provide deep insights that pave the way
for future growth. The Medidata Clinical Cloud is the primary
technology solution powering clinical trials for 18 of the world's
top 25 global pharmaceutical companies and is used by 18 of the top
25 medical device developers—from study design and planning through
execution, management and reporting.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171019005751/en/
MedidataInvestor:Anthony D’Amico, +1
732-767-4331adamico@mdsol.comorMedia:Medidata
SolutionsErik Snider, +1 646-362-2997esnider@mdsol.com
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Apr 2024 to May 2024
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From May 2023 to May 2024